Pure Global
NCT06344728

A Study to Assess the Relative Bioavailability of Brensocatib Pediatric Oral Solution to Oral Tablets in Healthy Participants

A Phase 1, Open-Label, Randomized, Two-Period Crossover Study to Assess the Relative Bioavailability of Brensocatib Pediatric Oral Solution to Oral Tablets Following Single Oral Doses in Healthy Subjects
Insmed Incorporated·Phase 1·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Healthy Participants
Drug/Device/Intervention
Brensocatib Oral Solution
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Insmed Incorporated
Location
Dallas, United States of America
Timeline & enrollment
Phase
Phase 1
Start date
Apr 30, 2024
End date
May 21, 2024
Enrollment
24 participants
Primary outcome

Relative Bioavailability Between Brensocatib Pediatric Oral Solution and Oral Tablets for Area Under the Concentration-time Curve from Time 0 Extrapolated to Infinity (AUC∞) of Brensocatib in Plasma

Summary

The primary purpose of this study is to determine the relative bioavailability of brensocatib
 between the pediatric oral solution and oral tablets in healthy participants.

ICD-10 classifications
Seeking and accepting physical, nutritional and chemical interventions known to be hazardous and harmfulHealthy person accompanying sick personRoutine general health check-up of sports teamsObesityPersons with potential health hazards related to communicable diseases
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06344728
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06344728 through Pure Global AI's free database. This Phase 1 trial is sponsored by Insmed Incorporated and is currently Recruiting. The study focuses on Healthy Participants. Target enrollment is 24 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.